OOIR: Observatory of International Research

Papers

(The TQCC of Expert Review of Pharmacoeconomics & Outcomes Research is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
Social care data in the UK; current landscape, challenges, and future recommendations	36
How to create value with constrained budgets in oncological care? A narrative review	23
Direct medical and indirect absenteeism costs among working adult ADHD patients in the United States	21
Economic value of knowing BRCA status: BRCA testing for prostate cancer prevention and optimal treatment	19
The impact of changing the funding model for genetic diagnostics and improved access to personalized medicine in oncology	18
Indication-based pricing of the pharmaceuticals in Croatia: case-study	18
Clinical and economic impact analysis of viscosupplementation with hylan G-F 20 versus hyaluronic acids and no viscosupplementation for the treatment of knee osteoarthritis in Colombia	17
Adherence to augmentation therapy for the treatment of major depressive disorder	16
Engagement of medication users in the development and implementation of digital medication adherence technologies: a multi-stakeholder study	13
Cost-effectiveness analysis of tofacitinib for the treatment of moderate to severe rheumatoid arthritis: a systematic review and meta-analysis	13
Direct diabetes-related healthcare expenditures in Slovenia: recent evolution and future projections based on population-level data	12
The role of insurance policies in the drug pricing landscape	12
Time from approval to reimbursement recommendations in healthcare systems with centralized HTA processes. Focus on the Polish HTA agency	12
Consumption of antidepressants and economic austerity in Brazil	11
A projected cost-utility analysis of avacopan for the treatment of antineutrophil cytoplasmic antibody-associated vasculitis in Spain	11
Cost-effectiveness comparison of dalpiciclib and abemaciclib combined with an aromatase inhibitor as first-line treatment for HR+/HER2− advanced breast cancer	11
A methodological guide for implementing and interpreting results of probabilistic analysis	11
Burden of disease and costs of infections associated with cardiac implantable electronic devices	9
The impact of under-investment on health in Southern and Central Eastern European Countries	9
Mapping of the health of the Nation Outcomes Scale (HoNOS) and Positive and Negative Symptom Scale (PANSS) to the EQ-5D-3L in psychosis patients using the PHAMOUS study	9
Cost-effectiveness analysis of nivolumab-chemotherapy as first-line therapy for locally advanced/metastatic gastric cancer: a United States payer perspective	9
The impact of bone turnover marker on medication adherence and the health economics-related consequences	9
Cost effectiveness of non-pharmacological interventions for fatigue in patients with long-term conditions: a systematic literature review	9
The economic burden of biologic disease-modifying antirheumatic drugs in rheumatoid arthritis patients in the United States	8
International comparability of reference unit costs of education services: when harmonizing methodology is not enough (PECUNIA project)	8

Regulatory perspectives on post-market evidence generation schemes for high-risk medical devices: a systematic review	8
Cost-utility analysis of multiple sclerosis rehabilitation in Iran	8
Digital measures in epilepsy in low-resourced environments	7
Valuing quality of life for economic evaluations in cancer: navigating multiple methods	7
Health and economic impact of 20-valent pneumococcal conjugate vaccine for adults aged 66–84 years in Japan and Shiga prefecture	7
Impact of patient’s financial burden of COVID-19 treatment on antiviral prescription rates and clinical and economic outcomes	7
Assessment of the properties of the EQ-5D-5L in patients with type 2 diabetes mellitus: a systematic review and meta-analysis	7
An update on the economic burden of type 2 diabetes mellitus in China	7
Burden of illness among intermittent catheter users with non-neurogenic urinary retention in Denmark	7
Cost-effectiveness analysis of pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric/gastroesophageal junction cancer in the Chinese healthcare system	7
Pembrolizumab combined with chemotherapy versus placebo combined with chemotherapy for HER2-negative advanced gastric cancer in China: a cost-effectiveness analysis	7
Access to medicines, care, and services for multiple sclerosis patients in Central and Eastern European countries: a comparative analysis	7
Systematic reviews of machine learning in healthcare: a literature review	7
Economic value of toripalimab plus axitinib as first-line treatment for advanced renal cell carcinoma in China: a model-based cost-effectiveness analysis	7
Adherence to oral anticoagulants in patients with non-valvular atrial fibrillation: the role of patients’ characteristics and out-of-pocket payments	6
The socioeconomic burden of cervical cancer and its implications for strategies required to achieve the WHO elimination targets	6
Valuing prevention: lessons and recommendations from a Dutch expert committee	6
Qualitative research on the acceptance of evolving evidence for HTA body approval of innovative health technologies in selected European countries	6
Prevalence and direct costs of potentially inappropriate prescriptions in France: a population-based study	6
Cost-utility analysis of osimertinib and dacomitinib in the first-line treatment of advanced non-small cell lung cancer with EGFR mutation	6
Evaluation instruments for executive functions in children and adolescents: an update of a systematic review	6
Considering potential solutions for limitations and challenges in the health economic evaluation of gene therapies	6
Are quality-adjusted life years (QALYs) becoming more expensive? Evidence from economic evaluations of diabetic therapeutics	6
Physician and patient adherence in hypertension trials: a point of view on an important issue to resolve	6
Intravenous and subcutaneous vedolizumab for moderately to severely active ulcerative colitis in Iran: a model-based cost-effectiveness evaluation	6
Patients’ health related quality of life after massive weight loss reconstruction in the Netherlands	6
Cost-effectiveness of daratumumab in combination with lenalidomide and dexamethasone for relapsed and/or refractory multiple myeloma	6
Value elements and methods of value-based pricing for drugs in Japan: a systematic review	6
How relevant is the BMI for cost-of-illness studies in the 21st century?	6
Estimation of the economic burden of atrial fibrillation-related stroke in Greece	6
Real-world analysis of the economic and therapeutic burden in advanced breast cancer patients in Italy	6
Cost–utility analysis of dupilumab compared with endoscopic sinus surgery in patients with chronic rhinosinusitis with nasal polyps. Evaluation in Colombia, a developing country	6
Transdisciplinary health economics for 2050: the challenge of preventing the adverse health effects of obesity, inequalities, and climate change	5
The potential public health impact of new immunization strategies for the prevention of RSV in children in Panama	5
In-hospital economic burden of anastomotic leakage after colorectal anastomosis surgery: a real-world cost analysis in Italy	5
Precision medicine in Thoracic Oncology: understanding disparities to tackle inequities in access	5
Tenecteplase in managing acute ischemic stroke: a long-term cost–utility analysis in Iran	5
Clinical and economic outcomes associated with intravenous albumin fluid use in the intensive care unit: a retrospective cohort study	5
A cost analysis of a simplified model for HCV screening and treatment at a tertiary hospital in Zimbabwe	5
Economic benefits of global Collaborative Health technology	5
Mapping the World Health Organization Disability Assessment Scale 2.0 to the EQ-5D-5L in patients with mental disorders	5
Economic analysis of cerliponase alfa for treatment of late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2)	5
Developing the Lebanese health economic evaluation guideline	5
Reimagining pharmacoeconomics in the age of artificial intelligence: opportunities, challenges, and future directions	5
Determination of the economically justifiable price of cenobamate in the treatment of focal-onset seizures in adult patients with drug-resistant epilepsy in Spain	5
Budget impact analysis of transurethral water vapor therapy for treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia in the Spanish national healthcare system	5
Healthcare costs, resource utilization, and productivity loss associated with colorectal cancer screening	5
Development and implementation of a stratified enhanced recovery after surgery pathway for ventral hernia repair	5
The substantial costs to society associated with obesity – a Danish register-based study based on 2002-2018 data	5
Bridging the gap: enhancing medication adherence through research and innovation	5

Burden of disease of chronic pain in Ecuador	5
Adherence to asthma and COPD inhaled therapies in low- and middle-income countries: a narrative review	5
Incorporating diagnostic testing into economic evaluations of tumour-agnostic therapies	5
Cost-effectiveness of camrelizumab plus chemotherapy versus chemotherapy alone as first-line therapy in advanced or metastatic esophageal squamous cell carcinoma	5
Preferences of people with diabetes for diabetes care in Germany: a discrete choice experiment	4
The Economics of prevention and quality of care: policy insights from the EU’s COVID-19 response	4
Trastuzumab deruxtecan versus chemotherapy treated in patients with HER2-positive metastatic breast cancer: a cost-effectiveness analysis based on the DESTINY-Breast02 trial	4
Use of machine learning to predict bladder cancer survival outcomes: a systematic literature review	4
Secondary healthcare resource utilization and related costs associated with influenza-related hospital admissions in adult patients, England 2016 – 2020	4
How do patients value features of biological medicine in rheumatoid arthritis? A discrete choice experiment	4
Methodological standards for comparative effectiveness research: considerations for evidentiary review for medicare drug price negotiation	4
Psychometric properties of outcome measures for freezing of gait in Parkinson’s disease: a systematic review and meta-analysis	4
Value-based health care in Western countries: a scoping review on the implementation of patient-reported-outcomes sets for hospital-based interventions	4
A retrospective observational analysis of the real-world care pathway of people with hereditary transthyretin amyloidosis with polyneuropathy in Italy	4
Cost-effectiveness analysis of olaparib and niraparib as maintenance therapy for women with recurrent platinum-sensitive ovarian cancer	4
The Lebanese health economic evaluation guideline	4
The hidden burden of atopic dermatitis in central and Eastern European countries	4
Analysis of patients’ access to reimbursed biotechnological medicines for multiple sclerosis in Bulgaria and Greece	4
Work absenteeism, disability, and lost wages among patients with acute myeloid leukemia and their caregivers: a cohort study using US administrative claims and productivity data	4
Economic evaluation of reproductive carrier screening for recessive genetic conditions: a systematic review	4
The economic impact of pharmacist intervention during pandemics	4
Enhancing pharmacist intervention targeting based on patient clustering with unsupervised machine learning	4
Cost-utility of dapagliflozin plus standard treatment compared to standard treatment for the management of heart failure with reduced ejection fraction in Colombia	4
Changes in treatment pattern and costs in advanced hepatocellular carcinoma (HCC)	4
Using natural language processing to analyze unstructured patient-reported outcomes data derived from electronic health records for cancer populations: a systematic review	4
Economic burden of comorbidities among COPD Patients hospitalized for acute exacerbations: an analysis of a commercially insured population	4
Pharmaceutical innovativeness index: methodological approach for assessing the value of medicines – a case study of oncology drugs	4
Value assessment of new interventions for Alzheimer’s disease dementia in Japan based on literature review and group interview	3
Lorlatinib as a first-line treatment of adult patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: Α cost-effectiveness analysis in Greece	3
Economic burden of cervical cancer and premalignant lesions associated with human papilloma virus: a societal perspective	3
How do hospital characteristics and ties relate to the uptake of second-generation biosimilars? A longitudinal analysis of Portuguese NHS hospitals, 2015–2021	3
Exploring the approach to parameter uncertainty in early economic evaluations of surgical technology – a systematic review	3
Access and pricing of medicines for patients with rare diseases in the European Union: an industry perspective	3
Assessing the impact of kidney cancer-related premature mortality and productivity loss in Greece and Portugal	3
Public value judgments about the criteria for reimbursement of medicines in South Korea	3
Inebilizumab for neuromyelitis optica spectrum disorders in Italy: a budget impact model	3
What are the costs of managing neck and low back pain in Brazil? Investigation of a ten-year period from the perspective of the Brazilian public health system	3
Can artificial intelligence separate the wheat from the chaff in systematic reviews of health economic articles?	3
Healthcare resource utilization and associated costs in patients with metastatic castration-resistant prostate cancer in Greece	3
Evaluating reporting of patient-reported outcomes in peptic ulcer disease: a meta-epidemiological study of randomized controlled trials	3
Cost-utility of sintilimab plus chemotherapy vs chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction cancer in China	3
Burden of disease of chronic pain in Colombia	3
Systematic review of the impact of health care expenditure on health outcome measures: implications for cost-effectiveness thresholds	3
The impact of fibrodysplasia ossificans progressiva (FOP) on patients and their family members: results from an international burden of illness survey	3
Normative data and socio-demographic determinants of the dermatology life quality index in a large online sample of the Hungarian population	3
Comparative efficacy of later-line therapies for metastatic colorectal cancer: a network meta-analysis of survival curves	3
Perspectives in prospective comparative economic evaluations: a systematic review	3
Correction	3
Cost and health impact analysis of herpes zoster vaccination in Norway	3
Assessment of Quality of Life 8-Dimension (AQoL-8D): translation, validation, and application in two Dutch trials in patients with epilepsy and schizophrenia	3
Costs for global guideline-based diagnosis of mucormycosis in patients with neutropenia, hematopoietic stem cell, or solid organ transplantation – a perspective of the German healthcare system	3
Cost-effectiveness of toripalimab plus chemotherapy versus chemotherapy as first-line treatment for advanced non-small cell lung cancer in China: a societal perspective	3
Implementing a Managed Entry Agreement Framework in Cyprus	3
The impact of comprehensive public hospital reform on economic burden of inpatients with chronic obstructive pulmonary disease: evidence from a pilot city in western China	3
Design and testing of a health economic Markov model for treatment of anorexia nervosa	3
Barriers to digital endpoints in data collection in low and middle-income countries	3
Patient-relevance of outcome measures in breast cancer clinical trials: a cross-sectional comparative analysis of patient preferences and trials conducted between 2014 and 2024	3
Evaluating discrete choice experiment willingness to pay [DCE-WTP] analysis and relative social willingness to pay [RS-WTP] analysis in a health technology assessment of a treatment for an ultra-rare	3
Improved medication adherence in COPD patients using tiotropium or tiotropium olodaterol with the HealthPrize digital behavior change program	3
Cost-effectiveness of first-line sintilimab plus chemotherapy versus chemotherapy for advanced esophageal carcinoma in China	3
System dynamics simulation for evaluating implementation strategies of genomic sequencing: tutorial and conceptual model	3
The short-term impact of copayment reductions for government subsidised medicines in Australia	3
Perceptions of risk sharing agreements in South Korea from the viewpoints of key stakeholders: a convergent parallel mixed approach	3
Capturing the holistic value of biosimilars in Europe – part 1: a historical perspective	3
A roadmap for applying machine learning when working with privacy-sensitive data: predicting non-response to treatment for eating disorders	3